Trial set to investigate new fertility drug

Article

Enrollment is under way for a national randomized study to assess the efficacy of a new fertility drug that would require one weekly injection rather than daily injections to stimulate the ovaries.

 

Enrollment is under way for a national randomized study to assess the efficacy of a new fertility drug that would require one weekly injection rather than daily injections to stimulate the ovaries.

Women between 35 and 42 years of age may qualify for a cycle of in vitro fertilization at no cost, according to an announcement from the Women’s and Infant’s Hospital of Rhode Island in Providence, which is one of the centers participating in the trial. The hospital’s Center for Reproduction and Infertility is enrolling patients for the study in Providence, Boston, and 9 other locations.

“This new drug would require a single injection that lasts 7 days” to stimulate the ovaries to produce eggs instead of the daily injections required by traditional infertility treatment, explains lead investigator Bala Bhagavath, MD.

“This is obviously much easier for the patient, and we’re hoping it will be equally, if not more, effective than the current drugs available,” Bhagavath says.

More information about the study is available from Patty Pursue at the Center for Reproduction and Infertility, (401) 453-7500, extension 8404.

Related Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.